4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $176 | -28.5% | 13,813 | +1.4% | 0.00% | – |
| Q2 2023 | $246 | -11.5% | 13,616 | -15.7% | 0.00% | – |
| Q1 2023 | $278 | -36.2% | 16,161 | -17.7% | 0.00% | -100.0% |
| Q4 2022 | $436 | -99.7% | 19,634 | -0.1% | 0.00% | – |
| Q3 2022 | $158,000 | +132.4% | 19,661 | +102.6% | 0.00% | – |
| Q2 2022 | $68,000 | -80.4% | 9,705 | -57.7% | 0.00% | – |
| Q1 2022 | $347,000 | +10.2% | 22,944 | +59.6% | 0.00% | – |
| Q4 2021 | $315,000 | +23.0% | 14,374 | +51.4% | 0.00% | – |
| Q3 2021 | $256,000 | +36.9% | 9,495 | +22.3% | 0.00% | – |
| Q2 2021 | $187,000 | +23.0% | 7,761 | +121.7% | 0.00% | – |
| Q1 2021 | $152,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 945,382 | $22,765,000 | 5.92% |
| Octagon Capital Advisors LP | 831,267 | $20,017,000 | 4.15% |
| BVF INC/IL | 2,005,862 | $48,301,000 | 1.81% |
| Casdin Capital, LLC | 1,115,555 | $26,863,000 | 0.68% |
| Eagle Health Investments LP | 57,090 | $1,375,000 | 0.47% |
| Soleus Capital Management, L.P. | 100,800 | $2,427,000 | 0.37% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $94,825,000 | 0.29% |
| ArrowMark Colorado Holdings LLC | 1,029,897 | $24,800,000 | 0.19% |
| Perceptive Advisors | 750,512 | $18,072,000 | 0.12% |
| Virtus ETF Advisers LLC | 7,642 | $184,000 | 0.08% |